The Russian pharmaceutical market is expected resume its growth this year, both in volume and value terms, amid the ongoing recovery of the Russian economy from the financial crisis and its consequences, according to recent statements of analysts at the Russian Ministry of Health, reports The Pharma Letter’s local correspondent.
According to their forecast, this year the Russian market will increase by 6%-7% in value terms to 1.3 trillion roubles (~$23 billion), compared to 2016, while in 2018 it will rise a further 9%. In volume terms, the market should grow by 10%-12% during the period of 2017-2018.
It is expected that this year the growth of the market will be mainly driven by public procurement, that should significantly increase this year, due to the planned increase of drug purchases for state needs by the end of the current year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze